|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
DeSantis CE, Bray F, Ferlay J,
Lortet-Tieulent J, Anderson BO and Jemal A: International variation
in female breast cancer incidence and mortality rates. Cancer
Epidemiol Biomarkers Prev. 24:1495–1506. 2015.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Ibrahim AS, Khaled HM, Mikhail NN, Baraka
H and Kamel H: Cancer incidence in Egypt: Results of the national
population-based cancer registry program. J Cancer Epidemiol.
2014(437971)2014.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Michailidou K, Hall P, Gonzalez-Neira A,
Ghoussaini M, Dennis J, Milne RL, Schmidt MK, Chang-Claude J,
Bojesen SE, Bolla MK, et al: Large-scale genotyping identifies 41
new loci associated with breast cancer risk. Nat Genet. 45353–361.
(361e1-e2)2013.PubMed/NCBI View
Article : Google Scholar
|
|
5
|
Garcia-Closas M, Couch FJ, Lindstrom S,
Michailidou K, Schmidt MK, Brook MN, Orr N, Rhie SK, Riboli E,
Feigelson HS, et al: Genome-wide association studies identify four
ER negative-specific breast cancer risk loci. Nat Genet. 45392–398.
(398e1-e2)2013.PubMed/NCBI View
Article : Google Scholar
|
|
6
|
Deng N, Zhou H, Fan H and Yuan Y: Single
nucleotide polymorphisms and cancer susceptibility. Oncotarget.
8:110635–110649. 2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Sternlicht MD, Bissell MJ and Werb Z: The
matrix metalloproteinase stromelysin-1 acts as a natural mammary
tumor promoter. Oncogene. 19:1102–1113. 2000.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Verma S, Kesh K, Gupta A and Swarnakar S:
An overview of matrix metalloproteinase 9 polymorphism and gastric
cancer risk. Asian Pac J Cancer Prev. 16:7393–7400. 2015.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Toroghi F, Mashayekhi F, Montazeri V,
Saedi HS and Zivar S: Association of MMP-9 promoter polymorphism
and breast cancer among Iranian patients. Eur J Oncol. 22:38–42.
2017.
|
|
10
|
Liu D, Guo H, Li Y, Xu X, Yang K and Bai
Y: Association between polymorphisms in the promoter regions of
matrix metalloproteinases (MMPs) and risk of cancer metastasis: A
meta-analysis. PLoS One. 7(e31251)2012.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Li X, Qu L, Zhong Y, Zhao Y, Chen H and
Daru L: Association between promoters polymorphisms of matrix
metalloproteinases and risk of digestive cancers: A meta-analysis.
J Cancer Res Clin Oncol. 139:1433–1447. 2013.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Okamoto K, Ishida C, Ikebuchi Y, Mandai M,
Mimura K, Murawaki Y and Yuasa I: The genotypes of IL-1 beta and
MMP-3 are associated with the prognosis of HCV-related
hepatocellular carcinoma. Intern Med. 49:887–895. 2010.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Motovali-Bashi M, Hojati Z and Hajihoseiny
S: The role of matrix metalloproteinase-3 functional 5A/6A promoter
polymorphism in tumor cell progression and metastasis of breast
cancer. Iran J Biotechnol. 6:45–9. 2008.
|
|
14
|
Sadeghi M, Motovali-bashi M and Hojati Z:
MMP-9 promoter polymorphism associated with tumor progression of
breast cancer in Iranian population. Int J Integrat Biol. 6:33–37.
2009.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Gencer S, Cebeci A and Irmak-Yazicioglu
MB: Matrix metalloproteinase gene expressions might be oxidative
stress targets in gastric cancer cell lines. Chin J Cancer Res.
25:322–333. 2013.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Chouchane L, Boussen H and Sastry KS:
Breast cancer in Arab populations: Molecular characteristics and
disease management implications. Lancet Oncol.
14(e417-e424)2013.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Blons H, Gad S, Zinzindohoué F, Manière I,
Beauregard J, Tregouet D, Brasnu D, Beaune P, Laccourreye O and
Laurent-Puig P: Matrix metalloproteinase 3 polymorphism: A
predictive factor of response to neoadjuvant chemotherapy in head
and neck squamous cell carcinoma. Clin Cancer Res. 10:2594–2599.
2004.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Ding C, Chen X, Zhang PT, Huang JP, Xu Y,
Chen N and Zhong LJ: Matrix Metalloproteinase-3-1171 5A/6A
Polymorphism (rs35068180) is Associated with Risk of Periodontitis.
Sci Rep. 5(11667)2015.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Lei H, Hemminki K, Altieri A, Johansson R,
Enquist K, Hallmans G, Lenner P and Försti A: Promoter
polymorphisms in matrix metalloproteinases and their inhibitors:
Few associations with breast cancer susceptibility and progression.
Breast Cancer Res Treat. 103:61–69. 2007.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Srivastava P, Gangwar R, Kapoor R and
Mittal RD: Bladder cancer risk associated with genotypic
polymorphism of the matrix metalloproteinase-1 and 7 in North
Indian population. Dis Markers. 29:37–46. 2010.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Padala C, Tupurani MA, Puranam K, Gantala
S, Shyamala N, Kondapalli MS, Gundapaneni KK, Mudigonda S, Galimudi
RK, Kupsal K, et al: Synergistic effect of collagenase-1 (MMP1),
stromelysin-1 (MMP3) and gelatinase-B (MMP9) gene polymorphisms in
breast cancer. PLoS One. 12(e0184448)2017.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Abdraboh NR and Bayoumi FA: Gene
polymorphism of matrix metalloproteinases 3 and 9 in breast cancer.
Gene Rep. 5:151–156. 2016. View Article : Google Scholar
|
|
24
|
Chiranjeevi P, Spurthi KM, Rani NS, Kumar
GR, Aiyengar TM, Saraswati M, Srilatha G, Kumar GK, Sinha S, Kumari
CS, et al: Gelatinase B (-1562C/T) polymorphism in tumor
progression and invasion of breast cancer. Tumour Biol.
35:1351–1356. 2014.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Chaudhary AK, Pandya S, Mehrotra R and
Singh M and Singh M: Role of functional polymorphism of matrix
metalloproteinase-2 (-1306 C/T and -168 G/T) and MMP-9 (-1562 C/T)
promoter in oral submucous fibrosis and head and neck squamous cell
carcinoma in an Indian population. Biomarkers. 16:577–586.
2011.
|
|
26
|
Przybylowska K, Kluczna A, Zadrozny M,
Krawczyk T, Kulig A, Rykala J, Kolacinska A, Morawiec Z, Drzewoski
J and Blasiak J: Polymorphisms of the promoter regions of matrix
metalloproteinases genes MMP-1 and MMP-9 in breast cancer. Breast
Cancer Res Treat. 95:65–72. 2006.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Fu F, Wang C, Chen LM, Huang M and Huang
HG: The influence of functional polymorphisms in matrix
metalloproteinase 9 on survival of breast cancer patients in a
Chinese population. DNA Cell Biol. 32:274–282. 2013.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Amălinei C, Căruntu ID, Giuşcă SE and
Bălan RA: Matrix metalloproteinases involvement in pathologic
conditions. Rom J Morphol Embryol. 51:215–228. 2010.PubMed/NCBI
|
|
29
|
Fan SH, Wang YY, Lu J, Zheng YL, Wu DM,
Zhang ZF, Shan Q, Hu B, Li MQ and Cheng W: CERS2 suppresses tumor
cell invasion and is associated with decreased V-ATPase and
MMP-2/MMP-9 activities in breast cancer. J Cell Biochem.
116:502–513. 2015.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Tabouret E, Bertucci F, Pierga JY, Petit
T, Levy C, Ferrero JM, Campone M, Gligorov J, Lerebours F, Roché H,
et al: MMP2 and MMP9 serum levels are associated with favorable
outcome in patients with inflammatory breast cancer treated with
bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study.
Oncotarget. 7:18531–18540. 2016.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Jafari M, Pirouzi A, Mohsenzadeh M, Kusari
AA and Hajihosseini S: Association of MMP 9-1562C/T single
nucleotide polymorphism with the susceptibility to lung cancer
disease in South Iranian population. J Med Med Res. 4:2494–2502.
2014.PubMed/NCBI View Article : Google Scholar
|
|
32
|
McColgan P and Sharma P: Polymorphisms of
matrix metalloproteinases 1, 2, 3 and 9 and susceptibility to lung,
breast and colorectal cancer in over 30,000 subjects. Int J Cancer.
125:1473–1478. 2009.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Yang X, Hu JW, Qiu MT, Li M, Yin R, Wang
J, Xu L and Zhang Q: Association of matrix metalloproteinase-3-1171
(5A>6A) polymorphism with cancer risk: A meta-analysis of 41
studies. PLoS One. 9(e87562)2014.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Fanjul-Fernández M, Folgueras AR, Cabrera
S and López-Otín C: Matrix metalloproteinases: Evolution, gene
regulation and functional analysis in mouse models. Biochim Biophys
Acta. 1803:3–19. 2010.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Medley TL, Kingwell BA, Gatzka CD, Pillay
P and Cole TJ: Matrix metalloproteinase-3 genotype contributes to
age-related aortic stiffening through modulation of gene and
protein expression. Circ Res. 92:1254–1261. 2003.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Zhang B, Ye S, Herrmann SM, Eriksson P, de
Maat M, Evans A, Arveiler D, Luc G, Cambien F, Hamsten A, et al:
Functional polymorphism in the regulatory region of gelatinase B
gene in relation to severity of coronary atherosclerosis.
Circulation. 99:1788–1794. 1999.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Youssef NS and Hakim SA: Association of
Fascin and matrix metalloproteinase-9 expression with poor
prognostic parameters in breast carcinoma of Egyptian women. Diagn
Pathol. 9(136)2014.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Yousef EM, Tahir MR, St-Pierre Y and
Gaboury LA: MMP-9 expression varies according to molecular subtypes
of breast cancer. BMC Cancer. 14(609)2014.
|
|
39
|
Jormsjö S, Whatling C, Walter DH, Zeiher
AM, Hamsten A and Eriksson P: Allele-specific regulation of matrix
metalloproteinase-7 promoter activity is associated with coronary
artery luminal dimensions among hypercholesterolemic patients.
Arterioscler Thromb Vasc Biol. 21:1834–1839. 2001.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Rahimi Z, Yari K and Rahimi Z: Matrix
metalloproteinase-9-1562T allele and its combination with MMP-2-735
C allele are risk factors for breast cancer. Asian Pac J Cancer
Prev. 16:1175–1179. 2015.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Sugimoto M, Yoshida S, Kennedy S, Deguchi
M, Ohara N and Maruo T: Matrix metalloproteinase-1 and -9 promoter
polymorphisms and endometrial carcinoma risk in a Japanese
population. J Soc Gynecol Investig. 13:523–529. 2006.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Song J, Su H, Zhou YY and Guo LL:
Prognostic value of matrix metalloproteinase 9 expression in breast
cancer patients: A meta-analysis. Asian Pac J Cancer Prev.
14:1615–1621. 2013.PubMed/NCBI View Article : Google Scholar
|
